METHODS: Online quantitative interviews and cost analysis were performed. Infectious disease specialists (IDS), hospital pharmacists (HP) and nurses were asked about their perception of potential differences in HRU between CAB + RPV LA vs. daily oral ART, among other concepts of interest. Spanish official tariffs were applied as unit costs to the HRU estimates (€2022).
RESULTS: 120 responders (n = 40 IDS, n = 40 HP, n = 40 nurses) estimated an average number of annual visits per patient by speciality (IDS, HP, and nurse, respectively) of 3.3 vs. 3.7; 4.4 vs. 6.2; 6.1 vs. 3.9, for CAB + RPV LA vs. daily oral ART, and 3.0 vs. 3.2; 4.8 vs. 5.8; 6.9 vs. 4.9, respectively when adjusting by corresponding specialist responses. Estimation by the total sample led to an annual total cost per patient of €2,076 vs. €2,473, being €2,032 vs. €2,237 after adjusting by corresponding HCP, for CAB + RPV LA vs. daily oral ART.
CONCLUSIONS: These results suggest that the implementation of CAB + RPV LA in NHS hospitals would not incur in increased HRU-related costs compared to current daily oral ARTs, being potentially neutral or even cost-saving.
方法:进行在线定量访谈和成本分析。传染病专家(IDS),医院药剂师(HP)和护士被问及他们对CAB+RPVLA与HRU之间潜在差异的看法日常口腔艺术,在其他兴趣概念中。西班牙官方关税作为单位成本适用于HRU估计(2022欧元)。
结果:120名响应者(n=40IDS,n=40HP,n=40名护士)按专业估计每位患者的平均年度就诊次数(IDS,HP,护士,分别)3.3与3.7;4.4vs.6.2;6.1vs.3.9,适用于CAB+RPVLA与日常口腔艺术,和3.0vs.3.2;4.8vs.5.8;6.9vs.4.9,分别由相应的专家响应进行调整。按总样本估算导致每位患者的年度总费用为2,076欧元,而不是€2,473,为€2,032vs.经过相应的HCP调整后的2,237欧元,CAB+RPVLAvs.日常口腔艺术。
结论:这些结果表明,与目前的日常口服ART相比,在NHS医院实施CAB+RPVLA不会增加HRU相关费用,可能保持中立甚至节省成本。